直肠给予吲哚美辛预防ESWL后胰腺炎(RIPEP):随机对照试验研究方案
BACKGROUND: Pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is the first-line therapy for large pancreatic duct stones. Although it is a highly effective and safe procedure for the fragmentation of pancreatic stones, it is still not complication-free.…
要点
- 胰腺体外冲击波碎石术(P-ESWL)是大胰管结石的一线治疗,但胰腺炎是其最常见并发症。
- 欧洲、美国及日本消化内镜学会指南推荐所有ERCP患者预防性直肠给予吲哚美辛。
- RIPEP试验旨在确定直肠吲哚美辛能否减少P-ESWL后胰腺炎的发生及严重程度。
核心结论
- RIPEP试验旨在证明直肠给予吲哚美辛可降低P-ESWL后胰腺炎的发生率和严重程度,并使接受P-ESWL的患者获益。
研究设计与样本
- RIPEP研究为前瞻性、随机、双盲、安慰剂对照试验。
- 患者被随机分配至术前直肠给予吲哚美辛组或安慰剂组。
主要发现
- 主要终点为P-ESWL后胰腺炎的发生率。
- 次要终点包括胰腺炎的严重程度、无症状性高淀粉酶血症的发生率及其他并发症。
关键数值与推荐
- 欧洲、美国及日本消化内镜学会指南推荐对所有接受ERCP的患者预防性直肠给予吲哚美辛。
- 纳入标准为慢性胰腺炎伴胰腺结石且结石直径>5 mm。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is the first-line therapy for large pancreatic duct stones. Although it is a highly effective and safe procedure for the fragmentation of pancreatic stones, it is still not complication-free. Just like endoscopic retrograde cholangiopancreatography (ERCP), pancreatitis is the most common complication. To date, nonsteroidal anti-inflammatory drugs (NSAIDs) have proven to be the only effective prophylactic medication for post-ERCP pancreatitis and the European, American and Japanese Society for Gastrointestinal Endoscopy guidelines have recommended prophylactic rectally administered indomethacin for all patients undergoing ERCP. Given the little research about effective prevention for post P-ESWL pancreatitis, we aim to determine whether rectally administered indomethacin can reduce post-ESWL-pancreatitis. METHODS/DESIGN: The RIPEP study is a prospective, randomized, double-blinded, placebo-controlled trial. One thousand three hundred and seventy patients with chronic pancreatitis and pancreatic stones (>5 mm in diameter) treated with P-ESWL at Changhai Hospital will be randomly allocated to rectally administered indomethacin or placebo therapy before the procedure. The primary endpoint is the incidence of post-ESWL pancreatitis. Secondary endpoints include the severity of pancreatitis, occurrence rate of asymptomatic hyperamylasemia and other complications. DISCUSSION: The RIPEP trial is designed to show that rectally administered indomethacin reduces the development and severity of post-ESWL pancreatitis and benefits patients treated with P-ESWL. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02797067 . Registered on 17 November 2016.
引用
- Qian YY, Chen H, Tang XY, et al. Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29096689. doi:10.1186/s13063-017-2250-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。